[Cool]

5
Comment
Favorite

CaptainMiya
2021-07-22

[Cool]

3 Surprising Stocks That Have Crushed the Market so Far This Year

They're not the growth stocks you're probably used to being huge winners.

3 Surprising Stocks That Have Crushed the Market so Far This Year

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

Top
Latest

No comments yet

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":172635347,"tweetId":"172635347","gmtCreate":1626957979789,"gmtModify":1703481310681,"author":{"id":3583738006388208,"idStr":"3583738006388208","authorId":3583738006388208,"authorIdStr":"3583738006388208","name":"CaptainMiya","avatar":"https://static.tigerbbs.com/48b66794427d9d57f06bb85d96e46757","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":101,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p><span>[Cool]&nbsp;</span><br></p></body></html>","htmlText":"<html><head></head><body><p><span>[Cool]&nbsp;</span><br></p></body></html>","text":"[Cool]","highlighted":1,"essential":1,"paper":1,"likeSize":5,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/172635347","repostId":2153153678,"repostType":4,"repost":{"id":"2153153678","kind":"highlight","pubTimestamp":1626956340,"share":"https://www.laohu8.com/m/news/2153153678?lang=&edition=full","pubTime":"2021-07-22 20:19","market":"us","language":"en","title":"3 Surprising Stocks That Have Crushed the Market so Far This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2153153678","media":"Motley Fool","summary":"They're not the growth stocks you're probably used to being huge winners.","content":"<p>There's a lot of talk about the possibility of a stock market crash. There's also increased volatility in the market, with rising concerns about the delta variant. However, the reality is that the stock market is still performing very well. The <b>S&amp;P 500</b> index is up nearly 16% year to date.</p>\n<p>Some of the S&amp;P 500 stocks that were the biggest winners in 2020 aren't faring nearly as well now. But others have taken their places. Here are three surprising stocks that have crushed the market so far this year.</p>\n<p>Image source: Getty Images.</p>\n<h3>HCA Healthcare</h3>\n<p>Shares of&nbsp;<b>HCA Healthcare</b> (NYSE:HCA) have skyrocketed more than 50% so far in 2021. That's more than triple the return for the S&amp;P 500 index. Why is the hospital chain having such a banner year? Chalk it up to a COVID-19 recovery.</p>\n<p>HCA CEO Sam Hazen said in the company's recent second-quarter earnings call that HCA \"experienced a strong rebound in demand for our services,\" thanks to a lower impact from the pandemic. Hazen noted that COVID-19 admissions in Q2 were only 3% of HCA's total admissions, compared to 10% in Q1.</p>\n<p>Hospitals were hit hard last year during the worst of the pandemic. The biggest problem was that many more lucrative non-urgent surgeries had to be delayed. Those surgeries are no longer being pushed back, benefiting HCA.</p>\n<p>Is HCA's strength only temporary? The company doesn't think so. It expects demand will remain strong throughout the rest of 2021. HCA also looks for growth in the demand for healthcare services beyond this year.</p>\n<h3>Idexx Laboratories</h3>\n<p><b>Idexx Laboratories</b> (NASDAQ:IDXX) shares soared 90% last year. It didn't look like the veterinary-products stock would perform all that well for much of the first half of 2021, though. Idexx lagged behind the S&amp;P 500 through early June. However, the stock is now up 34% year to date -- double the return of the major index.</p>\n<p>The company's acquisition of ezyVet in June helped boost investors' confidence about Idexx's prospects. The deal enables Idexx to expand its cloud software offerings with ezyVet's practice information-management system for veterinarians.</p>\n<p>Idexx projects that its revenue will increase between 14.5% and 16.5% for full-year 2021. The company's fortunes should be boosted by strong momentum in the companion-animal healthcare market, in particular.</p>\n<p>The long-term opportunity for Idexx is enormous. The company estimates its global total addressable market size is around $33 billion annually. Idexx currently only serves roughly 5% of this potential market.</p>\n<h3>Eli Lilly</h3>\n<p>It's unusual for big pharmaceutical stocks to crush the market. But that's exactly what&nbsp;<b>Eli Lilly</b> (NYSE:LLY) has done so far this year. Lilly's shares have vaulted more than 40% higher year to date.</p>\n<p>Lilly has had a few setbacks, though. The U.S. Food and Drug Administration (FDA) pushed back its approval decision for Olumiant in treating severe atopic dermatitis to review additional data. Also, an FDA advisory committee overwhelmingly voted that Lilly's and <b>Pfizer</b>'s proposed risk evaluation and mitigation strategy (REMS) for experimental painkiller tanezumab will ensure that the drug's benefits are greater than its risks.</p>\n<p>Still, the good news for Lilly outweighed the bad news. Probably the most important of the company's positive developments was its decision to pursue accelerated approval for Alzheimer's disease candidate donanemab, based on phase 2 data. Lilly initially opted not to take this route, but changed its mind after the FDA approved <b>Biogen</b>'s Alzheimer's disease drug Aduhelm.</p>\n<p>The FDA's decision on accelerated approval for donanemab will no doubt be pivotal in whether or not Lilly's share price will continue to climb significantly. Even if the agency gives a thumbs down, though, Lilly could still have a path to approval with its ongoing late-stage study of the drug in treating Alzheimer's disease.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Surprising Stocks That Have Crushed the Market so Far This Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Surprising Stocks That Have Crushed the Market so Far This Year\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-22 20:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/22/3-surprising-stocks-that-have-crushed-the-market-s/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>There's a lot of talk about the possibility of a stock market crash. There's also increased volatility in the market, with rising concerns about the delta variant. However, the reality is that the ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/22/3-surprising-stocks-that-have-crushed-the-market-s/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"161125":"标普500","513500":"标普500ETF",".SPX":"S&P 500 Index","OEX":"标普100","SDS":"两倍做空标普500ETF","UPRO":"三倍做多标普500ETF","OEF":"标普100指数ETF-iShares","SPXU":"三倍做空标普500ETF","SH":"标普500反向ETF","SSO":"两倍做多标普500ETF","IVV":"标普500指数ETF"},"source_url":"https://www.fool.com/investing/2021/07/22/3-surprising-stocks-that-have-crushed-the-market-s/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2153153678","content_text":"There's a lot of talk about the possibility of a stock market crash. There's also increased volatility in the market, with rising concerns about the delta variant. However, the reality is that the stock market is still performing very well. The S&P 500 index is up nearly 16% year to date.\nSome of the S&P 500 stocks that were the biggest winners in 2020 aren't faring nearly as well now. But others have taken their places. Here are three surprising stocks that have crushed the market so far this year.\nImage source: Getty Images.\nHCA Healthcare\nShares of HCA Healthcare (NYSE:HCA) have skyrocketed more than 50% so far in 2021. That's more than triple the return for the S&P 500 index. Why is the hospital chain having such a banner year? Chalk it up to a COVID-19 recovery.\nHCA CEO Sam Hazen said in the company's recent second-quarter earnings call that HCA \"experienced a strong rebound in demand for our services,\" thanks to a lower impact from the pandemic. Hazen noted that COVID-19 admissions in Q2 were only 3% of HCA's total admissions, compared to 10% in Q1.\nHospitals were hit hard last year during the worst of the pandemic. The biggest problem was that many more lucrative non-urgent surgeries had to be delayed. Those surgeries are no longer being pushed back, benefiting HCA.\nIs HCA's strength only temporary? The company doesn't think so. It expects demand will remain strong throughout the rest of 2021. HCA also looks for growth in the demand for healthcare services beyond this year.\nIdexx Laboratories\nIdexx Laboratories (NASDAQ:IDXX) shares soared 90% last year. It didn't look like the veterinary-products stock would perform all that well for much of the first half of 2021, though. Idexx lagged behind the S&P 500 through early June. However, the stock is now up 34% year to date -- double the return of the major index.\nThe company's acquisition of ezyVet in June helped boost investors' confidence about Idexx's prospects. The deal enables Idexx to expand its cloud software offerings with ezyVet's practice information-management system for veterinarians.\nIdexx projects that its revenue will increase between 14.5% and 16.5% for full-year 2021. The company's fortunes should be boosted by strong momentum in the companion-animal healthcare market, in particular.\nThe long-term opportunity for Idexx is enormous. The company estimates its global total addressable market size is around $33 billion annually. Idexx currently only serves roughly 5% of this potential market.\nEli Lilly\nIt's unusual for big pharmaceutical stocks to crush the market. But that's exactly what Eli Lilly (NYSE:LLY) has done so far this year. Lilly's shares have vaulted more than 40% higher year to date.\nLilly has had a few setbacks, though. The U.S. Food and Drug Administration (FDA) pushed back its approval decision for Olumiant in treating severe atopic dermatitis to review additional data. Also, an FDA advisory committee overwhelmingly voted that Lilly's and Pfizer's proposed risk evaluation and mitigation strategy (REMS) for experimental painkiller tanezumab will ensure that the drug's benefits are greater than its risks.\nStill, the good news for Lilly outweighed the bad news. Probably the most important of the company's positive developments was its decision to pursue accelerated approval for Alzheimer's disease candidate donanemab, based on phase 2 data. Lilly initially opted not to take this route, but changed its mind after the FDA approved Biogen's Alzheimer's disease drug Aduhelm.\nThe FDA's decision on accelerated approval for donanemab will no doubt be pivotal in whether or not Lilly's share price will continue to climb significantly. Even if the agency gives a thumbs down, though, Lilly could still have a path to approval with its ongoing late-stage study of the drug in treating Alzheimer's disease.","news_type":1},"isVote":1,"tweetType":1,"viewCount":528,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":6,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}